1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
暂无分享,去创建一个
Y. Bang | N. Sugimoto | D. Sakai | M. Ryu | H. Chung | S. Iwasa | K. Shitara | K. Yamaguchi | H. Kawakami | M. Sugihara | Junnam Lee | H. Yabusaki | Kaku Saito | Y. Kawaguchi | T. Kamio | A. Kojima | K. Saito